A Study Of Treatment Of Steroid Resistance And Steroid Dependent Nephrotic Syndrome By Myco-phenolate Mofetil & Deflazacort In Pediatric Age Group –A Study From Tribal Population In Developing State (India).
Keywords:
Mycophenolate Mofetil, Deflazacort, Steroid Dependent Nephrotic SyndromeAbstract
A total no of patients included in study are 28.The mean age of the patient is 11 ± 2.86 years. Out of 65 % patients are Male while 35 % patients are female. All patients are having Hypoalbuminea. The mean 24 hour urine protein is 3.1 ± 1.2 grams. 46 % Patients are Hypothyroid out of them 62 % was male & 38 % was female.72 % patients shows electrolyte imbalance.97 % patients shows abnormal usg findings in which, ascites, increased echotexture pleural effusion seen in 43.5%, 28%, 28.5 % respectively. Average weight of the Nephrotic Syndrome patient is 28 ± 13.69 kg. Average weight reduction in week duration is 6.78± 0.78 kg .Dose of Deflazacort used is 1 mg/kg body weight. Dose of Mycophenolate mofetil used is 12mg/kg body weight. No patients shows complication related to mycophenolate mofetil..96.4% patients shows improvement in 6 month follow up & only 1 patient had relapse because of irregular medication.
Downloads
References
10 Arvind Bagga & Mukta Mantan Indian J Med Res 122, July 2005, pp 13-28
Avioli LV. Potency ratio: A brief synopsis. Br J Rheumatol 1993;32(Suppl 2):24-6
Badid C, Desmouliere A, Laville M. Mycophenolate mofetil: implications for the treatment of glomerular disease. Nephrol Dial Transplant 2001; 16: 1752-1756.
Brister K, Yau CL, Slakey D. Enteric coating of mycophenolate reduces dosage adjust-ments.Transplant Proc. 2009;41:1657–9.
Brum S, Nolasco F, Sousa J, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc. 2008;40:752.
Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: A systematic review. BMC Neurol 2003;3:7
Ferraris JR, Krmar R, Flores D, Giogieri S, Díaz L, Tessler J. Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. Clin Nephrol. 1998;50:172–7.
Ferraris JR, Pasqualini T. Therapy with a new glucocorticoid: Effect of deflazacort on linear growth and growth hormone secretion in renal transplantation. J Rheumatol suppl. 1993;37:43–6.
idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-450
Joshi N, Rajeshwari K. Deflazacort. J Postgrad Med 2009;55:296-300.
McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM (2001) Time trends and ethnic patterns of childhood nephritic syndrome in Yorkshire, UK. Pediatr Nephrol 16:1040–1044
Passerini P. Treatment of idiopathic membranous nephropathy. G Ital Nefrol 2004; 21: 531-539.
Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in
Ponticelli C, Passerini P. Alkylating agents and purine nalogues in primary glomerulonephritis with nephrotic syndrome. Nephrol Dial Transplant 1991; 6: 381-388
Schärer K, Feneberg R, Klaus G, Paschen C, Wüster C, Mehls O, et al. Experience with deflazacort in children and adolescents after renal transplantation. Pediatr Nephrol. 2000;14:457–63.
Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007;2:968–75.
Zhao M, Chen X, Chen Y, Liu Z, Liu Y, Lu F, Zhang Y, Wang H. Clinical observations of mycophe-nolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology 2003; 8:105-109.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
